Vivos Therapeutics Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vivos Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vivos Therapeutics stock.
View analyst ratings for Vivos Therapeutics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Vivos Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vivos Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

1,448 employees have rated Vivos Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Vivos Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

2 brokerages have issued 1-year target prices for Vivos Therapeutics' stock. Their forecasts range from $12.00 to $12.00. On average, they expect Vivos Therapeutics' stock price to reach $12.00 in the next year. This suggests a possible upside of 69.7% from the stock's current price.
View analysts' price targets for Vivos Therapeutics or view Wall Street analyst' top-rated stocks.

Some companies that are related to Vivos Therapeutics include Presidio Property Trust (SQFT), WW Energy (WWNG), (GRSVU) (GRSVU), (SVOKU) (SVOKU), (TBA) (TBA), 378 (SCCB), ACE Convergence Acquisition (ACEVU), ACKRELL SPAC Partners I (ACKIU), Adit EdTech Acquisition (ADEXU), AEA-Bridges Impact (IMPXU), Aequi Acquisition (ARBGU), AllianzGI Artificial Intelligence Opportunities Fund (AIO), Altimeter Growth (AGCUU), ArcLight Clean Transition (ACTCU) and Athlon Acquisition (SWETU).
View all of VVOS's competitors.

(VVOS) raised $20 million in an IPO on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

Vivos Therapeutics trades on the NASDAQ under the ticker symbol "VVOS."

Vivos Therapeutics' quiet period expired on Wednesday, January 20th. Vivos Therapeutics had issued 3,500,000 shares in its initial public offering on December 11th. The total size of the offering was $21,000,000 based on an initial share price of $6.00. During Vivos Therapeutics' quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Shares of VVOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VVOS stock can currently be purchased for approximately $7.07.

Vivos Therapeutics has a market capitalization of $124.91 million.